Trial Profile
A Randomized, Open-label, Multicenter, Two Arm, Phase II Study to Evaluate Treatment Compliance, Efficacy and Safety of an Improved Deferasirox Formulation (Granules) in Pediatric Patients With Iron Overload
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Mar 2024
Price :
$35
*
At a glance
- Drugs Deferasirox (Primary) ; Deferasirox
- Indications Iron overload
- Focus Therapeutic Use
- Acronyms CALYPSO
- Sponsors Novartis; Novartis Healthcare; Novartis Pharmaceuticals
- 17 Jan 2024 Status changed from active, no longer recruiting to completed.
- 05 May 2023 Planned End Date changed from 18 Dec 2023 to 15 Dec 2023.
- 23 Feb 2023 This trial has been completed in France, according to European Clinical Trials Database record.